Batch‐dependent safety of COVID‐19 vaccines in the Czech Republic and comparison with data from Denmark

Documenti analoghi

• Nationwide estimates of SARS‐CoV‐2 infection fatality rates and numbers needed to vaccinate for COVID‐19 vaccines in 2024 in Austria
  di: Uwe Riedmann, et al.
  Pubblicazione: (2025)
• COVID‐19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy
  di: Heidi N. du Preez, et al.
  Pubblicazione: (2024)
• Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID‐19 vaccine
  di: Luis Jara‐Palomares, et al.
  Pubblicazione: (2024)
• Critical reflections on methodological uncertainties and the validity of a study on the association between lung damage in subjects who died from COVID‐19 and mRNA vaccines, and on ethical issues of data sharing
  di: Marco Alessandria, et al.
  Pubblicazione: (2025)
• Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey
  di: Derralynn A. Hughes, et al.
  Pubblicazione: (2025)